Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cocrystal Pharma Inc COCP

Healthcare
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function... see more

Recent & Breaking News (NDAQ:COCP)

Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

GlobeNewswire March 2, 2021

Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies

GlobeNewswire January 21, 2021

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement

GlobeNewswire January 19, 2021

Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium

GlobeNewswire January 14, 2021

Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021

GlobeNewswire January 12, 2021

Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

GlobeNewswire January 5, 2021

Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses

GlobeNewswire December 22, 2020

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

GlobeNewswire November 16, 2020

Cocrystal Pharma Selected to Present at the World Antiviral Conference

GlobeNewswire November 10, 2020

Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

GlobeNewswire November 6, 2020

Cocrystal Pharma Provides Update on Influenza A Program

GlobeNewswire October 19, 2020

Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

GlobeNewswire October 2, 2020

Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

GlobeNewswire September 8, 2020

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Cocrystal Pharma, Inc. and/or BioZone Pharmaceuticals, Inc. - COCP

GlobeNewswire September 7, 2020

Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares

GlobeNewswire August 31, 2020

Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million

GlobeNewswire August 26, 2020

Cocrystal Pharma Announces $10.0 Million Bought Deal Offering

GlobeNewswire August 26, 2020

Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

GlobeNewswire August 6, 2020

Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

GlobeNewswire August 4, 2020

Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

GlobeNewswire May 14, 2020